HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients

Inflamm Bowel Dis. 2024 Nov 4;30(11):2227-2231. doi: 10.1093/ibd/izad273.
No abstract available

Keywords: antidrug antibodies; loss of response; ustekinumab.

Plain language summary

It is unknown if inflammatory bowel disease patients carrying the HLA-DQA1*05 allele have a greater risk of immunogenicity to ustekinumab. We observed that ustekinumab-treated patients carrying the allele did not have increased immunogenicity or reduced efficacy/serum ustekinumab concentrations vs noncarriers.